GIP and GLP-1 Potentiate Sulfonylurea-Induced Insulin Secretion in Hepatocyte Nuclear Factor 1α Mutation Carriers

Sulfonylureas (SUs) provide an efficacious first-line treatment in patients with hepatocyte nuclear factor 1α (HNF1A) diabetes, but SUs have limitations due to risk of hypoglycemia. Treatment based on the incretin hormones glucose-dependent insulinotropic peptide (GIP) and glucagon-like peptide 1 (G...

Descripción completa

Detalles Bibliográficos
Autores principales: Christensen, Alexander S., Hædersdal, Sofie, Storgaard, Heidi, Rose, Kathrine, Hansen, Nina L., Holst, Jens J., Hansen, Torben, Knop, Filip K., Vilsbøll, Tina
Formato: Online Artículo Texto
Lenguaje:English
Publicado: American Diabetes Association 2020
Materias:
Pharmacology and Therapeutics
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7458039/
https://www.ncbi.nlm.nih.gov/pubmed/32518064
http://dx.doi.org/10.2337/db20-0074

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7458039/
https://www.ncbi.nlm.nih.gov/pubmed/32518064
http://dx.doi.org/10.2337/db20-0074

Ejemplares similares